{
    "nct_id": "NCT02849990",
    "official_title": "A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy",
    "inclusion_criteria": "* Willing and able to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Documented histologically confirmed adenocarcinoma of the prostate\n* Willing to undergo prostatectomy as primary treatment for localized prostate cancer\n* High risk prostate cancer (per National Comprehensive Cancer Network [NCCN] criteria): Gleason score 8-10 or T3a or PSA > 20 ng/mL or very-high risk prostate cancer (per NCCN criteria): T3b-T4\n* Serum testosterone >= 150 ng/dL\n* Able to swallow the study drugs whole\n* Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing)\n* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug\n* Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)\n* Prior use of apalutamide, abiraterone acetate or degarelix\n* Prior or ongoing systemic therapy for prostate cancer including, but not limited to:\n\n  * Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin, degarelix)\n  * Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole)\n  * Antiandrogens (e.g. bicalutamide, nilutamide)\n  * Second generation antiandrogens (e.g. enzalutamide, apalutamide)\n  * Immunotherapy (e.g. sipuleucel-T, ipilimumab)\n  * Chemotherapy (e.g. docetaxel, cabazitaxel)\n* Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study\n* Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule\n* Absolute neutrophil count [ANC] < 1500/mm^3\n* Platelet count < 100,000/mm^3\n* Hemoglobin < 9 g/dL\n* Total bilirubin > 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN; Note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible\n* Abnormal kidney function (glomerular filtration rate GFR < 45 mL/min)\n* Serum albumin < 3 g/dL\n* Serum potassium < 3.5 mmol/L\n* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization\n* History of stroke within the last 5-years\n* History of gastrointestinal (GI) bleed requiring transfusion\n* History of peptic ulcer disease requiring treatment within the last 5-years\n* History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced or with asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring more than 2 days per week)\n* Uncontrolled hypertension\n* Gastrointestinal disorder affecting absorption\n* Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)\n* Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/ prednisolone once daily\n* Any condition that in the opinion of the investigator, would preclude participation in this study\n* Child Pugh class B & C\n* Pre-existing viral hepatitis",
    "miscellaneous_criteria": ""
}